Within prostate cancer, it has been well established that the oncogenic ETS factors, most often ERG, become overexpressed through chromosomal rearrangements and elicit several phenotypic changes that allow for the progression from a benign neoplasia to an invasive carcinoma, when paired with PTEN deletion [39, 44, 45]. The gene discussed is ERG; the disease is neoplasm.